Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00447642 · ClinicalTrials.gov registry record · Phase 3
Study to Assess LX201 for Prevention of Corneal Allograft Rejection or Graft Failure in Subjects Who Have Experienced One or More Rejection Episodes Following Penetrating Keratoplasty
A Phase 3 study, sponsored by Lux Biosciences.
- Terminated
- Registry status
- Phase 3
- Development phase
- 122
- Enrollment target
NCT00447642 is a Phase 3 study that was terminated before completion, run by Lux Biosciences. The registered enrollment target is 122 participants.
The verdict
NCT00447642, a Phase 3 study, was terminated before completion, sponsored by Lux Biosciences.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 122 participants
- Enrollment target
Study Summary
This study will evaluate the use of LX201 to prevent future graft rejection episodes and/or graft failure in patients who have undergone corneal transplantation and who have recently experienced a rejection episode due to an immune response.
Interventions
- OTHER Placebo
- DRUG LX201
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 122 participants |
| Start Date | 2007-04 |
| Est. Completion | 2010-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00447642
The ClinicalTrials.gov registry entry for NCT00447642 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 122 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Lux Biosciences, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00447642 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00447642 about?
NCT00447642 is a clinical study titled "Study to Assess LX201 for Prevention of Corneal Allograft Rejection or Graft Failure in Subjects Who Have Experienced One or More Rejection Episodes Following Penetrating Keratoplasty". This study will evaluate the use of LX201 to prevent future graft rejection episodes and/or graft failure in patients who have undergone corneal transplantation and who have recently experienced a rejection episode due to an immune response.
What is the current status of trial NCT00447642?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 122 participants. The study started on 2007-04. Estimated completion is 2010-01.
What interventions are being tested in trial NCT00447642?
The interventions under investigation include: Placebo (OTHER), LX201 (DRUG).
Who is sponsoring clinical trial NCT00447642?
This trial is sponsored by Lux Biosciences, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.